- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.10. | Aegis Capital Corp. Acted as Sole Bookrunner on a $4.2 Million Initial Public Offering for Polyrizon Ltd. | 231 | ACCESSWIRE | NEW YORK, NY / ACCESSWIRE / October 30, 2024 / Aegis Capital Corp. acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ:PLRZ).About Polyrizon Ltd.Polyrizon... ► Artikel lesen | |
| 30.10. | Polyrizon Ltd.: Polyrizon Announces Closing of $4.2 Million Initial Public Offering | 93 | GlobeNewswire (Europe) | Raanana, Israel, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (the "Company" or "PLRZ"), a development stage biotech company specializing in the development of innovative medical device hydrogels... ► Artikel lesen | |
| 29.10. | Polyrizon Ltd.: Polyrizon Announces Pricing of $4.2 Million Initial Public Offering and Listing on the Nasdaq Capital Market Under New Ticker "PLRZ" | 143 | GlobeNewswire (Europe) | Raanana, Israel, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (the "Company" or "PLRZ"), a development stage biotech company specializing in the development of innovative medical device hydrogels... ► Artikel lesen | |
| POLYRIZON Aktie jetzt für 0€ handeln | |||||
| 21.10. | Polyrizon Ltd. - 8-A12B, Registration of securities | - | SEC Filings | ||
| 02.10. | Polyrizon Ltd. - F-1/A, Registration statement for certain foreign private issuers | 2 | SEC Filings | ||
| 23.09. | Polyrizon Ltd. - F-1/A, Registration statement for certain foreign private issuers | 1 | SEC Filings | ||
| 16.09. | Polyrizon Ltd. - F-1/A, Registration statement for certain foreign private issuers | 1 | SEC Filings | ||
| 04.09. | Polyrizon Ltd. - F-1/A, Registration statement for certain foreign private issuers | - | SEC Filings | ||
| 19.08. | SciSparc and Polyrizon sign global agreement for pain therapy | 1 | Pharmaceutical Technology | ||
| 19.08. | Polyrizon pays $3M for license to SciSparc's preclinical cannabinoid pain therapy | 1 | FierceBiotech | ||
| 16.08. | SciSparc licenses SCI-160 pain drug program to Polyrizon | 2 | Seeking Alpha | ||
| 14.08. | Polyrizon Ltd. - F-1/A, Registration statement for certain foreign private issuers | 1 | SEC Filings |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ADMA BIOLOGICS | 21,370 | 0,00 % | Adma Biologics Aktie: Erholung nach starkem Kursrückgang | ||
| RECURSION PHARMACEUTICALS | 6,040 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| EVOTEC | 9,920 | +0,15 % | Evotec: Extreme Ausschläge | Größer könnten die Gegensätze wohl kaum sein. Die Aktie von Evotec hat im zurückliegenden Jahren einen massiven Einbruch erfahren. Auf 52-Wochen-Sicht gehört sie zu den schlechtesten Aktien im SDAX.... ► Artikel lesen | |
| QIAGEN | 39,905 | +2,74 % | DAX fehlen die Impulse. Qiagen deutet Gegenbewegung an | ||
| QUANTUM-SI | 1,400 | 0,00 % | Quantum-Si Inc - 8-K, Current Report | ||
| 89BIO | 7,980 | 0,00 % | 89bio, Inc.: 89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting 2024 | SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for... ► Artikel lesen | |
| LONGBOARD PHARMACEUTICALS | 59,76 | 0,00 % | Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... ► Artikel lesen | |
| RELAY THERAPEUTICS | 4,660 | 0,00 % | Aktie von Relay Therapeutics erreicht 52-Wochen-Tief bei 5,59 US-Dollar | ||
| STRUCTURE THERAPEUTICS | 32,710 | 0,00 % | Structure Therapeutics reports Q3 results | ||
| SPRINGWORKS THERAPEUTICS | 37,440 | 0,00 % | SpringWorks started at outperform by Evercore ahead of FDA decision | ||
| 4D MOLECULAR THERAPEUTICS | 8,410 | 0,00 % | Analyst Expectations For 4D Molecular Therapeutics' Future | ||
| DYNE THERAPEUTICS | 30,000 | 0,00 % | Dyne Therapeutics: Leitender Vizepräsident veräußert Aktien im Wert von 77.127 US-Dollar | ||
| CULLINAN THERAPEUTICS | 12,580 | 0,00 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 | Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of CLN-978 in autoimmune diseases Cullinan will share details of global Phase... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 6,740 | 0,00 % | Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) | ||
| VERVE THERAPEUTICS | 4,550 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024... ► Artikel lesen |
Das Unternehmen POLYRIZON LTD kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,933 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu POLYRIZON LTD finden Sie auf Wallstreet Online.
